 |
449 Diseases |  |
58 Trials |
|
58 Trials |  |
3605 News |  |
| «12...89101112131415161718...2425» |
- | Leukine (sargramostim) / Partner Therap, Danyelza (naxitamab) - Y / mAbs Therap
Enrollment change: Study of Chemoimmunotherapy for High-Risk Neuroblastoma (clinicaltrials.gov) - Jun 6, 2018
P1, N=20, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
N=10 --> 20
- | Leukine (sargramostim) / Partner Therap, Panvac-VF (falimarev/inalimarev) / Bavarian Nordic
Trial completion, Trial completion date, Combination therapy, Metastases: PANVAC-V and PANVAC-F Vaccines Plus Sargramostim to Treat Advanced Cancer (clinicaltrials.gov) - Jun 4, 2018
P2, N=51, Completed, Sponsor: National Cancer Institute (NCI)
N=10 --> 20 Active, not recruiting --> Completed | Trial completion date: Apr 2019 --> May 2018
- | Trial completion date, Trial primary completion date: NMA Allogeneic Hematopoietic Cell Transplant in Hematologic Cancer/Disorders (clinicaltrials.gov) - Jun 2, 2018
P2, N=41, Active, not recruiting, Sponsor: Roswell Park Cancer Institute
Active, not recruiting --> Completed | Trial completion date: Apr 2019 --> May 2018 Trial completion date: May 2018 --> Aug 2018 | Trial primary completion date: May 2018 --> Aug 2018
- | Leukine (sargramostim) / Partner Therap, Panvac-VF (falimarev/inalimarev) / Bavarian Nordic
Trial completion date, Combination therapy, Metastases: PANVAC-V and PANVAC-F Vaccines Plus Sargramostim to Treat Advanced Cancer (clinicaltrials.gov) - Jun 2, 2018
P2, N=51, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: May 2018 --> Aug 2018 | Trial primary completion date: May 2018 --> Aug 2018 Trial completion date: Apr 2018 --> Apr 2019
- | Rituxan (rituximab) / Roche, Zevalin (ibritumomab tiuxetan) / Servier, Aurobindo
Trial completion: Rituximab, Yttrium Y 90 Ibritumomab Tiuxetan, Melphalan, and Autologous Peripheral Stem Cell Transplant in Treating Patients With Previously Treated Multiple Myeloma (clinicaltrials.gov) - Jun 2, 2018
P1, N=30, Completed, Sponsor: Mayo Clinic
Trial completion date: Apr 2018 --> Apr 2019 Active, not recruiting --> Completed
- | Lorbrena (lorlatinib) / Pfizer, Azedra (iobenguane I 131) / Lantheus
Enrollment open: Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL) (clinicaltrials.gov) - May 31, 2018
P3, N=774, Recruiting, Sponsor: Children's Oncology Group
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- | Zevalin (ibritumomab tiuxetan) / Spectrum Pharma, Servier, Mundipharma
P1 data, Journal: A phase 1 trial of (90)Y-Zevalin radioimmunotherapy with autologous stem cell transplant for multiple myeloma. (Pubmed Central) - May 25, 2018
P1
In MM, the MTD of (90)Y-Zevalin with HDM is 18 Gy to the liver. The addition of radiation with novel delivery methods such as radioimmunotherapy combined with standard transplant regimens warrants further study.Bone Marrow Transplantation advance online publication, 4 September 2017; doi:10.1038/bmt.2017.164.
- | Leukine (sargramostim) / Partner Therap, SurVaxM (SVN53-67/M57-KLH peptide vaccine) / MimiVax
Trial completion date, Trial primary completion date: SVN53-67/M57-KLH Peptide Vaccine in Treating Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance Therapy (clinicaltrials.gov) - May 4, 2018
P1, N=18, Recruiting, Sponsor: Roswell Park Cancer Institute
The addition of radiation with novel delivery methods such as radioimmunotherapy combined with standard transplant regimens warrants further study.Bone Marrow Transplantation advance online publication, 4 September 2017; doi:10.1038/bmt.2017.164. Trial completion date: Nov 2019 --> Nov 2023 | Trial primary completion date: Nov 2018 --> Nov 2022
- | Leukine (sargramostim) / Partner Therap, Reolysin (pelareorep) / Oncolytics, Andrus Reo
Enrollment change, Trial withdrawal, Metastases: REO13 Melanoma With of Without GM-CSF (clinicaltrials.gov) - May 4, 2018
P1/2, N=0, Withdrawn, Sponsor: University of Leeds
Trial completion date: Nov 2019 --> Nov 2023 | Trial primary completion date: Nov 2018 --> Nov 2022 N=16 --> 0 | Not yet recruiting --> Withdrawn
- || Leukine (sargramostim) / Partner Therap
Enrollment change, Metastases: Docetaxel and Vinorelbine Plus Sargramostim in Metastatic Malignant Melanoma (clinicaltrials.gov) - May 3, 2018
P2, N=52, Completed, Sponsor: John P. Fruehauf
N=16 --> 0 | Not yet recruiting --> Withdrawn N=82 --> 52
- | Leukine (sargramostim) / Partner Therap
Enrollment change, Trial completion date, Trial withdrawal, Trial primary completion date, Biopsy: Sargramostim or Hypertonic Saline Before Sentinel Lymph Node Biopsy in Treating Patients With Stage IB-II Melanoma (clinicaltrials.gov) - Apr 30, 2018
P3, N=0, Withdrawn, Sponsor: Jonsson Comprehensive Cancer Center
N=82 --> 52 N=380 --> 0 | Trial completion date: Mar 2019 --> Aug 2017 | Recruiting --> Withdrawn | Trial primary completion date: Mar 2018 --> Aug 2017
- | Keytruda (pembrolizumab) / Merck (MSD), Leukine (sargramostim) / Partner Therap
Enrollment open, Metastases: Pembrolizumab and GM-CSF in Biliary Cancer (clinicaltrials.gov) - Apr 27, 2018
P2, N=42, Recruiting, Sponsor: Robin Kate Kelley
N=380 --> 0 | Trial completion date: Mar 2019 --> Aug 2017 | Recruiting --> Withdrawn | Trial primary completion date: Mar 2018 --> Aug 2017 Active, not recruiting --> Recruiting
- | Leukine (sargramostim) / Partner Therap, LucaVax (tertomotide) / GemVax & KAEL
Trial completion, Metastases: Immunochemoradiotherapy in Patients With Pancreatic Cancer (clinicaltrials.gov) - Apr 12, 2018
P1, N=11, Completed, Sponsor: Providence Health & Services
Active, not recruiting --> Recruiting Active, not recruiting --> Completed
- | Leukine (sargramostim) / Partner Therap, Yervoy (ipilimumab) / BMS
Trial completion, Combination therapy, Metastases: Ipilimumab and Sargramostim in Treating Patients With Metastatic Prostate Cancer (clinicaltrials.gov) - Apr 10, 2018
P1, N=42, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||| Leukine (sargramostim) / Partner Therap, NeuVax (nelipepimut-S) / Dr. Reddy's, Herceptin (trastuzumab) / Roche
Enrollment closed: Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax (clinicaltrials.gov) - Apr 6, 2018
P2, N=300, Active, not recruiting, Sponsor: George E. Peoples
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- | Leukine (sargramostim) / Partner Therap
Trial completion date, Trial primary completion date, Immune cell: Neoadjuvant Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Cutaneous Stage L-lll Melanoma (clinicaltrials.gov) - Apr 3, 2018
P4, N=20, Recruiting, Sponsor: Mayo Clinic
Recruiting --> Active, not recruiting Trial completion date: Dec 2017 --> Dec 2019 | Trial primary completion date: Nov 2017 --> Nov 2019
- | Leukine (sargramostim) / Partner Therap, Rituxan (rituximab) / Roche
Trial completion date, Trial primary completion date: Rituximab Plus CHOP With Sargramostim in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma (clinicaltrials.gov) - Apr 2, 2018
P2, N=52, Active, not recruiting, Sponsor: University of Southern California
Trial completion date: Dec 2017 --> Dec 2019 | Trial primary completion date: Nov 2017 --> Nov 2019 Trial completion date: Jan 2019 --> Jan 2020 | Trial primary completion date: Jan 2018 --> Jan 2019
- | Leukine (sargramostim) / Partner Therap
Trial completion: PROPEL: Treadmill Exercise and GM-CSF Study to Improving Functioning in Peripheral Artery Disease (PAD) (clinicaltrials.gov) - Mar 31, 2018
P=N/A, N=210, Completed, Sponsor: Northwestern University
Trial completion date: Jan 2019 --> Jan 2020 | Trial primary completion date: Jan 2018 --> Jan 2019 Active, not recruiting --> Completed
- Leukine (sargramostim) / Partner Therap
Trial completion date: Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer (clinicaltrials.gov) - Mar 30, 2018
P1, N=7, Active, not recruiting, Sponsor: Roswell Park Cancer Institute
Active, not recruiting --> Completed Trial completion date: Apr 2018 --> Sep 2018
- | Leukine (sargramostim) / Partner Therap, SurVaxM (SVN53-67/M57-KLH peptide vaccine) / MimiVax
Enrollment closed: NCI-2015-00694: SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma (clinicaltrials.gov) - Mar 27, 2018
P2, N=64, Active, not recruiting, Sponsor: Roswell Park Cancer Institute
Trial completion date: Apr 2018 --> Sep 2018 Recruiting --> Active, not recruiting
- || biropepimut-S (GL-0817) / Gliknik
Trial completion date, Trial primary completion date: Safety and Efficacy Study of GL-0817 (With Cyclophosphamide) for the Prevention of Recurrence of Squamous Cell Carcinoma of the Oral Cavity (clinicaltrials.gov) - Mar 26, 2018
P2, N=80, Recruiting, Sponsor: Gliknik Inc.
Recruiting --> Active, not recruiting Trial completion date: Mar 2020 --> Dec 2020 | Trial primary completion date: Mar 2020 --> Dec 2020
- | Keytruda (pembrolizumab) / Merck (MSD), Leukine (sargramostim) / Partner Therap
Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date, Metastases: Pembrolizumab and GM-CSF in Biliary Cancer (clinicaltrials.gov) - Mar 13, 2018
P2, N=42, Active, not recruiting, Sponsor: Robin Kate Kelley
Trial completion date: Mar 2020 --> Dec 2020 | Trial primary completion date: Mar 2020 --> Dec 2020 Recruiting --> Active, not recruiting | N=27 --> 42 | Trial completion date: Sep 2019 --> Mar 2021 | Trial primary completion date: Dec 2017 --> Mar 2019
- | Recentin (cediranib) / AstraZeneca
Trial completion date, Monotherapy, Metastases: Sunitinib or Cediranib for Alveolar Soft Part Sarcoma (clinicaltrials.gov) - Mar 12, 2018
P2, N=70, Recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting | N=27 --> 42 | Trial completion date: Sep 2019 --> Mar 2021 | Trial primary completion date: Dec 2017 --> Mar 2019 Trial completion date: Jun 2018 --> Jun 2019
- | Lorbrena (lorlatinib) / Pfizer, Azedra (iobenguane I 131) / Lantheus
Trial initiation date: Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL) (clinicaltrials.gov) - Mar 12, 2018
P3, N=774, Not yet recruiting, Sponsor: Children's Oncology Group
Trial completion date: Jun 2018 --> Jun 2019 Initiation date: Dec 2017 --> Apr 2018
- | Leukine (sargramostim) / Partner Therap
Trial completion date, Metastases: Vaccine Therapy and GM-CSF With or Without Low-Dose Aldesleukin in Treating Patients With Stage II, Stage III, or Stage IV Melanoma (clinicaltrials.gov) - Mar 6, 2018
P1, N=20, Active, not recruiting, Sponsor: Mayo Clinic
Initiation date: Dec 2017 --> Apr 2018 Trial completion date: Dec 2017 --> Dec 2018
- | humanised dinutuximab (Hu14.18K322A) / Essential Pharma
Trial completion date: Combination Chemotherapy, Monoclonal Antibody, and Natural Killer Cells in Treating Young Patients With Recurrent or Refractory Neuroblastoma (clinicaltrials.gov) - Mar 3, 2018
P1, N=34, Active, not recruiting, Sponsor: St. Jude Children's Research Hospital
Trial completion date: Dec 2017 --> Dec 2018 Trial completion date: Feb 2019 --> Oct 2018
- | Enrollment change: SPRING: High-Risk Neuroblastoma Chemotherapy Without G-CSF (clinicaltrials.gov) - Feb 22, 2018
P=N/A, N=13, Recruiting, Sponsor: Baylor College of Medicine
Trial completion date: Feb 2019 --> Oct 2018 N=21 --> 13
- | Leukine (sargramostim) / Partner Therap
Trial completion date, Trial primary completion date, Metastases: Radiofrequency Therapy-Induced Endogenous Heat-Shock Proteins With or Without Radiofrequency Ablation or Cryotherapy in Treating Patients With Stage IV Melanoma (clinicaltrials.gov) - Feb 13, 2018
P=N/A, N=23, Active, not recruiting, Sponsor: Mayo Clinic
N=21 --> 13 Trial primary completion date: May 2017 --> May 2018 | Trial completion date: May 2017 --> May 2018
- | Leukine (sargramostim) / Partner Therap, SurVaxM (SVN53-67/M57-KLH peptide vaccine) / MimiVax
Enrollment change: NCI-2015-00694: SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma (clinicaltrials.gov) - Feb 12, 2018
P2, N=65, Recruiting, Sponsor: Roswell Park Cancer Institute
Trial primary completion date: May 2017 --> May 2018 | Trial completion date: May 2017 --> May 2018 N=50 --> 65
- | Leukine (sargramostim) / Partner Therap, Panvac-VF (falimarev/inalimarev) / Bavarian Nordic
Phase classification, Combination therapy, Metastases: PANVAC-V and PANVAC-F Vaccines Plus Sargramostim to Treat Advanced Cancer (clinicaltrials.gov) - Jan 31, 2018
P2, N=51, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
N=50 --> 65 Phase classification: P1 --> P2
- | Leukine (sargramostim) / Partner Therap, Panvac-VF (falimarev/inalimarev) / Bavarian Nordic
Trial primary completion date, Combination therapy, Metastases: PANVAC-V and PANVAC-F Vaccines Plus Sargramostim to Treat Advanced Cancer (clinicaltrials.gov) - Jan 25, 2018
P1, N=51, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Phase classification: P1 --> P2 Trial primary completion date: Jan 2019 --> Apr 2018
- | Leukine (sargramostim) / Partner Therap
Trial completion, Enrollment change: Phase Ib Trial of Two Folate Binding Protein Peptide Vaccines (E39 and J65) in Breast and Ovarian Cancer Patients (clinicaltrials.gov) - Jan 25, 2018
P1/2, N=39, Completed, Sponsor: COL George Peoples, MD, FACS
Trial primary completion date: Jan 2019 --> Apr 2018 Active, not recruiting --> Completed | N=30 --> 39
- Leukine (sargramostim) / Partner Therap
Enrollment closed, IO biomarker: The Immuno-Response to Primary Cryotherapy for the Treatment of Prostate Cancer (clinicaltrials.gov) - Jan 19, 2018
P1, N=19, Active, not recruiting, Sponsor: University of Colorado, Denver
Active, not recruiting --> Completed | N=30 --> 39 Recruiting --> Active, not recruiting
- | Leukine (sargramostim) / Partner Therap
Trial primary completion date: Study of the Safety & Efficacy of Leukine (clinicaltrials.gov) - Jan 18, 2018
P2, N=40, Active, not recruiting, Sponsor: University of Colorado, Denver
Recruiting --> Active, not recruiting Trial primary completion date: Nov 2017 --> Nov 2018
- Leukine (sargramostim) / Partner Therap
Trial completion, Metastases: GENITOPE-9901: Vaccine Therapy Plus Sargramostim Following Chemotherapy in Treating Stage III or Stage IV Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Jan 16, 2018
P2, N=0, Completed, Sponsor: University of Nebraska
Trial primary completion date: Nov 2017 --> Nov 2018 Active, not recruiting --> Completed
- | Leukine (sargramostim) / Partner Therap
Trial completion: Vaccine Therapy Plus Sargramostim Following Chemotherapy in Previously Untreated Aggressive Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Jan 16, 2018
P2, N=0, Completed, Sponsor: University of Nebraska
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Leukine (sargramostim) / Partner Therap, Panvac-VF (falimarev/inalimarev) / Bavarian Nordic
Trial primary completion date, Combination therapy, Metastases: PANVAC-V and PANVAC-F Vaccines Plus Sargramostim to Treat Advanced Cancer (clinicaltrials.gov) - Jan 5, 2018
P1, N=51, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Trial primary completion date: Jan 2018 --> Jan 2019
- | humanised dinutuximab (Hu14.18K322A) / Essential Pharma
Trial completion, Enrollment change, Trial primary completion date: A Pilot Study of Immunotherapy Including Haploidentical NK Cell Infusion Following CD133+ Positively-Selected Autologous Hematopoietic Stem Cells in Children With High Risk Solid Tumors or Lymphomas (clinicaltrials.gov) - Dec 22, 2017
P1, N=8, Completed, Sponsor: St. Jude Children's Research Hospital
Trial primary completion date: Jan 2018 --> Jan 2019 Recruiting --> Completed | N=36 --> 8 | Trial primary completion date: Sep 2020 --> Dec 2017
- | Leukine (sargramostim) / Partner Therap
Enrollment open: GPAD-3: Granulocyte-Macrophage Stimulating Factor (GM-CSF) in Peripheral Arterial Disease (clinicaltrials.gov) - Dec 21, 2017
P2, N=176, Recruiting, Sponsor: Emory University
Recruiting --> Completed | N=36 --> 8 | Trial primary completion date: Sep 2020 --> Dec 2017 Not yet recruiting --> Recruiting
- Leukine (sargramostim) / Partner Therap
Trial termination, Trial primary completion date: Phase II GM-CSF Plus Mitoxantrone in Hormone Refractory Prostate Cancer (clinicaltrials.gov) - Dec 19, 2017
P2, N=10, Terminated, Sponsor: Stanford University
Not yet recruiting --> Recruiting Completed --> Terminated | Trial primary completion date: Jan 2009 --> Oct 2009; Low accrual
- | AST-302 / Aston Sci., EpiThany
Enrollment open, IO biomarker, Metastases: WOKVAC: Vaccine Therapy in Preventing Cancer Recurrence in Patients With Non-Metastatic, Node Positive, HER2 Negative Breast Cancer That is in Remission (clinicaltrials.gov) - Dec 11, 2017
P1, N=30, Recruiting, Sponsor: University of Washington
Completed --> Terminated | Trial primary completion date: Jan 2009 --> Oct 2009; Low accrual Suspended --> Recruiting
- | EGFR bi-armed autologous activated T cells / Barbara Ann Karmanos Cancer Institute
Enrollment closed, Enrollment change, Trial primary completion date, Combination therapy, PD(L)-1 Biomarker, IO biomarker, Metastases: NCI-2015-01942: BATS With in Combination With Low Dose IL-1 and GM-CSF for Advanced Pancreatic Cancer (clinicaltrials.gov) - Dec 7, 2017
P1/2, N=2, Active, not recruiting, Sponsor: Barbara Ann Karmanos Cancer Institute
Suspended --> Recruiting Suspended --> Active, not recruiting | N=43 --> 2 | Trial primary completion date: Dec 2016 --> Dec 2018
- | Leukine (sargramostim) / Partner Therap
Trial primary completion date: Trial of ID-Specific Donor Vaccinated Lymphocyte Infusion for Patients With Myeloma Relapsing or Failing to Achieve a Complete Remission After an Allogenic Transplant (clinicaltrials.gov) - Dec 5, 2017
P2, N=2, Terminated, Sponsor: M.D. Anderson Cancer Center
Suspended --> Active, not recruiting | N=43 --> 2 | Trial primary completion date: Dec 2016 --> Dec 2018 Trial primary completion date: Jul 2018 --> Feb 2017
- | AST-302 / Aston Sci., EpiThany
Trial suspension, Trial primary completion date, IO biomarker, Metastases: WOKVAC: Vaccine Therapy in Preventing Cancer Recurrence in Patients With Non-Metastatic, Node Positive, HER2 Negative Breast Cancer That is in Remission (clinicaltrials.gov) - Dec 2, 2017
P1, N=30, Suspended, Sponsor: University of Washington
Trial primary completion date: Jul 2018 --> Feb 2017 Recruiting --> Suspended | Trial primary completion date: Sep 2024 --> Dec 2019
- Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Trial primary completion date: Immunotherapy With NK Cell, Rituximab and Rhu-GMCSF in Non-Myeloablative Allogeneic Stem Cell Transplantation (clinicaltrials.gov) - Nov 30, 2017
P1, N=40, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Suspended | Trial primary completion date: Sep 2024 --> Dec 2019 Trial primary completion date: Sep 2018 --> Sep 2019
- | Torisel (temsirolimus) / Pfizer, Unituxin (dinutuximab) / United Therapeutics Corp, Ohara Pharma
Enrollment closed: Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed Neuroblastoma (clinicaltrials.gov) - Nov 24, 2017
P2, N=74, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Sep 2018 --> Sep 2019 Suspended --> Active, not recruiting
- || Libtayo (cemiplimab-rwlc) / Regeneron
Trial primary completion date: Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies (clinicaltrials.gov) - Nov 14, 2017
P1, N=398, Active, not recruiting, Sponsor: Regeneron Pharmaceuticals
Suspended --> Active, not recruiting Trial primary completion date: Jul 2019 --> Dec 2019
- | Leukine (sargramostim) / Partner Therap, FR Alpha Peptide Vaccine / National Cancer Institute
Enrollment open: Multi-epitope Folate Receptor Alpha Peptide Vaccine, GM-CSF, and Cyclophosphamide in Treating Patients With Triple Negative Breast Cancer (clinicaltrials.gov) - Nov 8, 2017
P2, N=280, Recruiting, Sponsor: Academic and Community Cancer Research United
Trial primary completion date: Jul 2019 --> Dec 2019 Active, not recruiting --> Recruiting
- | Zolinza (vorinostat) / Merck (MSD), Azedra (iobenguane I 131) / Lantheus, Unituxin (dinutuximab) / United Therapeutics Corp, Ohara Pharma
New P1 trial: MIBG With Dinutuximab +/- Vorinostat (clinicaltrials.gov) - Nov 6, 2017
P1, N=24, Not yet recruiting, Sponsor: New Approaches to Neuroblastoma Therapy Consortium
- | Leukine (sargramostim) / Partner Therap, Yervoy (ipilimumab) / BMS
Trial primary completion date, Combination therapy, Metastases: Ipilimumab and Sargramostim in Treating Patients With Metastatic Prostate Cancer (clinicaltrials.gov) - Oct 25, 2017
P1, N=42, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Recruiting Trial primary completion date: Aug 2003 --> Jan 2011